This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of treating neuropsychiatric symptoms (NPS) as separate comorbidities. The faculty also review emerging therapeutic approaches, including tau-targeting therapy for Alzheimer’s disease, as well as novel treatments for agitation and related NPS.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

This online CME activity explores the clinical complexity and real-world impact of systemic mastocytosis through both clinician insight and patient experience. Participants will examine the multisystem burden of this disease, challenges in diagnosis, and the importance of recognizing symptoms that are often underestimated. The program reviews current evidence-based and targeted treatment strategies to support personalized care across clinical settings. Faculty also goes in-depth on shared decision-making and integrating patient perspectives into management plans. Multidisciplinary approaches to monitoring treatment response, managing adverse events, and sustaining quality of life are also highlighted.

This educational series explores evolving strategies in the management of acute myeloid leukemia (AML) with a focus on targeted therapies. Faculty experts will review molecular diagnostics and guideline-driven use of FLT3 and menin inhibitors across treatment lines, including frontline, relapsed/refractory, and maintenance settings. Participants will examine clinical trial data, adverse event management, and practical applications through real-world case discussions. The activity emphasizes evidence-based sequencing, MRD assessment, and safety monitoring to support optimal patient outcomes.

On-demand webcast covering the latest advances in lipid management and atherosclerotic cardiovascular disease risk reduction, including the emerging role of lipoprotein(a), data on novel lipid-lowering therapies, and strategies for individualizing care for patients with hyperlipidemia.

Glaucoma care is shifting from a narrow focus on pressure targets to a broader, patient-centered approach that balances durable intraocular pressure (IOP) control with preservation of the ocular surface, comfort, and real-world adherence. But, daily practice often still defaults to drop-heavy regimens that can erode the very ocular surface on which long-term success depends. The chronic use of preserved topical medications can compromise the cornea and conjunctiva, perpetuating ocular surface disease (OSD) and ocular surface inflammation (OSI). These conditions not only degrade comfort and quality of life but also undermine adherence, accelerate treatment failure, and reduce the success rates of both medical and surgical interventions. Recent expert consensus underscores that every glaucoma patient should be screened for OSD/OSI, yet implementation remains inconsistent in daily practice. Contemporary perspectives and data support a shift toward ocular surface-sparing strategies, including preservative-free options, earlier laser strategies, and newer tear-restorative, anti-inflammatory, and neuromodulatory therapeutic options when OSD does occur.

Neurotrophic keratitis (NK) remains significantly underdiagnosed because early findings are easily mistaken for dry eye disease and other ocular surface disorders. Although reduced corneal sensitivity is the defining feature of NK, corneal sensitivity testing is not routinely performed, resulting in missed opportunities to identify stage 1 NK when intervention is most effective. Treatment at stage 1 can preserve corneal sensitivity and prevent progression to epithelial defects, but many clinicians may lack the confidence needed to initiate treatment earlier. This activity has been designed to improve clinicians’ ability to differentiate and diagnose NK and to select optimal treatment regimens based on evidence from recent studies and current guidelines.

Current guidelines recommend the use of second-generation therapies for the treatment of retinal diseases; however, limited head-to-head study data make it difficult to determine which strategies to use for specific patients and at what time. In this activity, experts in the field of retinal diseases provide their preferred management strategies based on real-world and long-term clinical data using 3 patient cases.